@ARTICLE{Hendouei, author = {Zarghami, Mehran and Azari, Ala and Ghasemi, Shaghayegh and Hormozpour, Mehdi and Hendouei, Narjes and }, title = {Availability of Drug Key Information on Package Inserts of Psychiatric Drugs Manufactured in Iranian Pharmaceutical Companies }, volume = {22}, number = {2}, abstract ={Objectives: The aim of this study was to examine information of package inserts of psychiatric drugs manufactured in Iranian pharmaceutical companies in line with safe prescription and use. Method: 104 brochures of 34 psychiatric drugs manufactured by 29 Iranian pharmaceutical companies were examined against a set of criteria compiled from the literature. The results were reported as numbers and percentages. Results: Information on drug class and action mechanism were given in 10 PIs, pharmacokinetic information in 6 and information on dose adjustment in case of concurrent use with known enzyme inhibitors or inducers drugs in 5 PIs. Also, Information from (human/animal) clinical studies on the safety or potential teratogenicity was available in 3 PIs. 12 PIs had full information on the symptoms of poisoning and required supportive initiatives. For the side effects, 15% of PIs provided qualitative information and 4% had pointed out the prevalence and incidence rate. Conclusion: The results of current study indicate lack of sufficient information in PIs of Iran-manufactured psychiatric drugs regarding their safe and appropriate use. Fundamental changes in these drugs’ PIs structure seem inevitable. }, URL = {http://ijpcp.iums.ac.ir/article-1-2602-en.html}, eprint = {http://ijpcp.iums.ac.ir/article-1-2602-en.pdf}, journal = {Iranian Journal of Psychiatry and Clinical Psychology}, doi = {}, year = {2016} }